Emergent BioSolutions (EBS) Earnings Date, Estimates & Call Transcripts

$7.60

+0.08 (+1.06%)

(As of 10:33 AM ET)

Upcoming Earnings Date: Dec. 9Estimated
Actual EPS (Aug. 6): -$2.32 Missed By -$1.35
Consensus EPS (Aug. 6): -$0.97

EBS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

EBS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Ad Crypto 101 Media

Perfect Crypto Buying Opportunity for 50 Cents

When cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious Bank

Go here to get full details on this crypto now.

Emergent BioSolutions Analyst EPS Estimates

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2024	1	($1.11)	($1.11)	($1.11)
Q2 2024	1	$0.78	$0.78	$0.78
Q3 2024	1	$0.83	$0.83	$0.83
Q4 2024	1	$1.59	$1.59	$1.59
FY 2024	4	$2.09	$2.09	$2.09
Q1 2025	1	$0.29	$0.29	$0.29
Q2 2025	1	$1.07	$1.07	$1.07

EBS Earnings Date and Information

Emergent BioSolutions last released its earnings data on August 6th, 2024. The biopharmaceutical company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($0.97) by $1.35. The business had revenue of $254.70 million for the quarter, compared to analyst estimates of $199.47 million. Emergent BioSolutions has generated ($11.01) earnings per share over the last year (($11.01) diluted earnings per share). Earnings for Emergent BioSolutions are expected to grow in the coming year, from ($1.98) to ($1.15) per share. Emergent BioSolutions has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, December 9th, 2024 based off prior year's report dates.

Emergent BioSolutions Earnings History by Quarter

Time Frame

Start Date

End Date

Export to Excel

Date	Quarter	Consensus Estimate	Reported EPS	Beat/Miss	GAAP EPS	Revenue Estimate	Actual Revenue
12/9/2024 (Estimated)	-	-	-	-	-	-	-
8/6/2024	Q2 2024	($0.97)	($2.32)	($1.35)	$0.74	$199.47 million	$254.70 million
5/1/2024	Q1 2024	($3.65)	$0.59	+$4.24	$1.01	-	$300.40 million
3/6/2024	Q4 2023	($0.33)	($0.77)	($0.44)	($0.59)	$247.63 million	$276.60 million
12/11/2023	Q3 2023	($0.12)	($1.44)	($1.32)	$2.20	$255.34 million	$270.50 million
8/8/2023	Q2 2023	($0.98)	($1.06)	($0.08)	$3.03	$216.17 million	$337.90 million
5/9/2023	Q1 2023	($1.67)	($3.17)	($1.50)	($2.69)	$142.85 million	$165.10 million
Get the Latest News and Ratings for EBS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.
2/27/2023	Q4 2022	$0.31	($0.31)	($0.62)	$1.14	$298.23 million	$330.70 million
11/8/2022	Q3 2022	($0.06)	($1.27)	($1.21)	($1.02)	$268.17 million	$240.00 million
8/1/2022	Q2 2022	$0.63	($0.86)	($1.49)	($0.59)	$268.77 million	$242.70 million
4/28/2022	Q1 2022	$0.24	$0.18	($0.06)	$0.43	$282.54 million	$307.50 million
2/24/2022	Q4 2021	$3.89	$4.50	+$0.61	$5.50	$676.90 million	$723.40 million
11/4/2021	Q3 2021	$2.35	($0.36)	($2.71)	($0.11)	$484.77 million	$329.00 million
7/29/2021	Q2 2021	$1.81	$0.33	($1.48)	$0.57	$415.73 million	$397.50 million
4/28/2021	Q1 2021	$0.97	$1.53	+$0.56	$1.78	$368.62 million	$343.00 million
2/17/2021	Q4 2020	$2.72	$3.67	+$0.95	$3.90	$588.39 million	$583.00 million
11/11/2020	Q3 2020	$2.12	$2.19	+$0.07	$3.65	$438.51 million	$385.20 million
7/30/2020	Q2 2020	$0.53	$1.98	+$1.45	$2.23	-	$394.70 million
4/30/2020	Q1 2020	$0.01	$0.01	-	$0.26	$198.79 million	$192.50 million
2/20/2020	Q4 2019	$1.67	$1.57	($0.10)	$2.25	$357.18 million	$360.40 million
11/6/2019	Q3 2019	$0.63	$1.21	+$0.58	$1.59	$289.16 million	$311.80 million

Emergent BioSolutions Earnings - Frequently Asked Questions

When is Emergent BioSolutions's earnings date?: Emergent BioSolutions has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, December 9th, 2024 based off last year's report dates. Learn more on EBS's earnings history.
What guidance has Emergent BioSolutions issued on next quarter's earnings?: Emergent BioSolutions issued an update on its third quarter 2024 earnings guidance on Tuesday, August, 6th. The company issued revenue guidance of $265.0 million-$315.0 million, compared to the consensus revenue estimate of $312.2 million.
Did Emergent BioSolutions beat their earnings estimates last quarter?: In the previous quarter, Emergent BioSolutions (NYSE:EBS) missed the analysts' consensus estimate of ($0.97) by $1.35 with a reported earnings per share (EPS) of ($2.32). Learn more on analysts' earnings estimate vs. EBS's actual earnings.
How can I listen to Emergent BioSolutions's earnings conference call?: The conference call for Emergent BioSolutions's latest earnings report can be listened to online. Listen to Conference Call
How can I read Emergent BioSolutions's conference call transcript?: The conference call transcript for Emergent BioSolutions's latest earnings report can be read online. Read Transcript
How much revenue does Emergent BioSolutions generate each year?: Emergent BioSolutions (NYSE:EBS) has a recorded annual revenue of $1.05 billion.
How much profit does Emergent BioSolutions generate each year?: Emergent BioSolutions (NYSE:EBS) has a recorded net income of -$760.50 million. EBS has generated -$11.01 earnings per share over the last four quarters.
What is Emergent BioSolutions's EPS forecast for next year?: Emergent BioSolutions's earnings are expected to grow from ($1.98) per share to ($1.15) per share in the next year.